CNSP · CNS Pharmaceuticals, Inc.
Market Cap
$8.43M
Shares
1.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.89
Open$5.77
Day$5.77–5.89
52W close$2.13–10.57
Avg vol 30d7K
Short int13K · 0.9% float · 2.9d
Short vol40%
Last earningsMar 12, 2020
DataJul 2025–Sep 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Jul 22, 2025; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+13%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
45%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+99%
trailing
YTD return
+12%
this year
Relative strength
+86%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-8% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.86% of float · ▲ +10.7% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
11 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
+92%
Y/Y
Free cash flow
$-13.8M
Quant / Vol
risk profile
Volatility
255%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
45%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-8% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.86% of float · ▲ +10.7% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
11 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $6 · 45%
Range high $11
vs 200-day avg +22%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNSP
this stock
CNS Pharmaceuticals, Inc.
|
$8.43M | +12.2% | — | — | 0.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +6.7% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jul 22, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNSP | +1.6% | +9.9% | +99.1% | -1.5% | +12.2% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | +2.1% | +11.2% | +86.4% | -0.8% | +0.5% |
Key facts
CIK
1729427
CUSIP
18978H508
13F (30d)
11 filings
10 filers
Visit website
Investor relations